Vertex Pharmaceuticals Incorporated
Compare market positioning with top industry peers
Explore Vertex Pharmaceuticals
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$12.0B
Market Cap
$121.0B
Employees
5,200
Vertex Pharmaceuticals is operating as the undisputed sovereign of cystic fibrosis treatment, extracting wildly lucrative, monopolistic revenues from its dominant Trikafta/Kaftrio franchise that has permanently transformed CF from a fatal disease into a manageable chronic condition. Under CEO Reshma Kewalramani, the biotech giant generated exactly $11.0 billion in revenue and maintains a $121.0 billion market cap with exactly 5200 employees. The financial narrative in 2026 is entirely defined by extraordinary pipeline diversification beyond CF; reinvesting its astronomical CF cash flows, Vertex extracts the beginning of its next growth chapter from its innovative non-opioid pain therapy suzetrigine and its transformative CRISPR-based sickle cell disease cure Casgevy.
Revenue Trend Analysis
YoY Change
+8.9%
2-Year CAGR
+10.3%
Peak Year
2025
Trend
Consistent Growth
Vertex Pharmaceuticals Incorporated has reported revenue across 3 fiscal years, compounding at +10.3% annually over 2 years. The most recent year saw a 8.9% increase versus the prior year. Revenue peaked in 2025 at $12.0B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | YoY Change |
|---|---|---|
| FY2025 | $12.0B | +8.9% |
| FY2024 | $11.0B | +11.7% |
| FY2023 | $9.9B | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Vertex Pharmaceuticals Incorporated reported approximately $11.0B in fiscal year 2025 with a team of 5,200 employees worldwide.
Vertex Pharmaceuticals Incorporated strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Biotechnology and Genetic Medicines is driven by steady cash generation and pricing power, enabling Vertex Pharmaceuticals Incorporated to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Vertex Pharmaceuticals Incorporated Revenue & Financials." CorpDigest, https://corpdigest.com/company/vertex/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Vertex Pharmaceuticals Incorporated reported $12B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/vertex/financials" target="_blank" rel="noopener">CorpDigest — Vertex Pharmaceuticals Incorporated financials</a></div>